Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
| Cat.No. | Product Name | Price |
|---|---|---|
| CSC-DC008310 | Panoply™ Human KLK3 Knockdown Stable Cell Line | Inquiry |
| CSC-SC008310 | Panoply™ Human KLK3 Over-expressing Stable Cell Line | Inquiry |
| CLOE-1198 | Human KLK3 HEK293 Cell Lysate | Inquiry |
| Cat.No. | Product Name | Price |
|---|---|---|
| AD08777Z | Human KLK3 adenoviral particles | Inquiry |
| LV16481L | human KLK3 (NM_001030048) lentivirus particles | Inquiry |
| LV16482L | human KLK3 (NM_001030050) lentivirus particles | Inquiry |
| LV16483L | human KLK3 (NM_001648) lentivirus particles | Inquiry |
| LV16484L | human KLK3 (NM_001030047) lentivirus particles | Inquiry |
| Cat.No. | Product Name | Price |
|---|---|---|
| SHH138233 | shRNA set against Human KLK3(NM_001030050.1) | Inquiry |
| SHH138251 | shRNA set against Human KLK3(NM_001030047.1) | Inquiry |
| SHH138287 | shRNA set against Human KLK3(NM_001030048.1) | Inquiry |
| SHH138305 | shRNA set against Human KLK3(NM_001648.2) | Inquiry |
| Cat.No. | Product Name | Price |
|---|---|---|
| RP00142 | Recombinant Human KLK3 (236AA, C-6His) | Inquiry |
| RP00189 | Recombinant Human KLK3 (244AA, C-6His) | Inquiry |
| Cat.No. | Product Name | Price |
|---|---|---|
| CDCL125053 | Human KLK3 ORF clone (NM_001030047.1) | Inquiry |
| CDFH010016 | Human KLK3 cDNA Clone(NM_001030047.1) | Inquiry |
| CDFH010017 | Human KLK3 cDNA Clone(NM_001030048.1) | Inquiry |
| CDFH010018 | Human KLK3 cDNA Clone(NM_001030050.1) | Inquiry |
| CDFH010019 | Human KLK3 cDNA Clone(NM_001648.2) | Inquiry |
| CDFH010020 | Human KLK3 cDNA Clone(NM_001648.2) | Inquiry |
| MiUTR1H-05396 | KLK3 miRNA 3'UTR clone | Inquiry |
| MiUTR1H-05397 | KLK3 miRNA 3'UTR clone | Inquiry |
| MiUTR1H-05398 | KLK3 miRNA 3'UTR clone | Inquiry |
| MiUTR1H-05399 | KLK3 miRNA 3'UTR clone | Inquiry |
| CDCL125055 | Human KLK3 ORF clone (NM_001030048.1) | Inquiry |
| CDCL125057 | Human KLK3 ORF clone (NM_001030050.1) | Inquiry |
| CDCS406734 | Human KLK3 ORF Clone (BC005307) | Inquiry |
| CDCS406735 | Human KLK3 ORF Clone (BC050595) | Inquiry |
Prostate-specific antigen (PSA), also known as γ-seminoprotein or kallikrein-related peptidase 3 (KLK3), is a single-chain glycoprotein and serine protease secreted by prostatic epithelial cells. In the bloodstream, PSA exists in both free (fPSA) and complexed (cPSA) forms and plays a role in semen liquefaction and sperm motility activation. Beyond its physiological functions, PSA is implicated in various signaling pathways associated with prostate cancer, including those governing proliferation, invasion, metastasis, angiogenesis, apoptosis, immune response, and tumor microenvironment regulation. These multifaceted roles make PSA a significant molecular target for prostate cancer treatment.
PSA is a well-established blood biomarker for prostate cancer recurrence, with serum levels correlating with disease progression. However, its diagnostic specificity is limited, leading to the development of enhanced assays such as PSA velocity, PSA density, the Prostate Health Index (PHI), and the 4Kscore, which aim to improve diagnostic accuracy by incorporating additional PSA-related metrics.
Figure 1. Proposed placement of KLK3 into the regulatory network of angiogenesis and lymphangiogenesis. (Lin HY, et al., 2021)
Functionally, PSA contributes to maintaining cancer cell growth and modulating apoptosis. Within the tumor microenvironment, PSA influences prostate cancer progression by affecting cell proliferation, angiogenesis, and metastatic potential. Notably, PSA can stimulate the expression of tumor suppressor genes and participate in immune responses against tumor cells by activating cytotoxic T lymphocytes (CTLs). Furthermore, PSA serves as a valuable imaging biomarker, aiding in the detection of malignant regions within the prostate and identifying metastatic sites.
Tumor Marker for Prostate Cancer: Under normal physiological conditions, PSA levels in serum are low, typically within the reference range of 0–4 ng/mL. However, malignant transformation of prostate tissue disrupts cellular architecture, leading to increased PSA leakage into the bloodstream and elevated serum concentrations. This characteristic elevation makes PSA a crucial tumor marker for prostate cancer detection and monitoring.
Targeted Therapies: Advancements in targeted therapies have focused on PSA and its associated signaling pathways. Approaches include the development of small-molecule inhibitors that target PSA-activated cell surface receptors or downstream signaling components. Additionally, bispecific antibodies have been engineered to simultaneously bind PSA and immune effector cells, such as T cells, thereby enhancing the immune-mediated cytotoxicity against tumor cells. Antibody-drug conjugates (ADCs) targeting PSA are also under investigation, wherein antibodies specific to PSA are conjugated with cytotoxic agents to deliver targeted chemotherapy to prostate cancer cells.
These therapeutic strategies are part of a broader effort to exploit PSA's dual role as both a biomarker and a functional participant in prostate cancer pathophysiology, aiming to improve diagnostic precision and treatment efficacy.
References